Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Furiex Pharmaceuticals has received fast track designation from the US Food and Drug Administration (FDA) for MuDelta, its novel diarrhea-predominant irritable bowel syndrome treatment.
Subscribe to our email newsletter
The FDA’s fast track programme is designed to facilitate the development and accelerate the review of new drugs intended to treat serious or life-threatening diseases and that show potential to address an unmet clinical need.
MuDelta, which is currently in Phase II clinical trials, is a novel mu-opioid receptor agonist and delta-opioid receptor antagonist in development for the treatment of diarrhea-predominant irritable bowel syndrome.
Early pre-clinical and Phase I clinical data of MuDelta indicate that this drug may provide effective relief for both pain and diarrheal symptoms of IBS-d, without causing constipation which is usually seen with mu receptor agonists.
Diarrhea-predominant irritable bowel syndrome or IBS-d is characterised by chronic abdominal pain and frequent diarrhea, and it affects approximately 12 million people in the US.